Cipla and Stempeutics launch Ciplostem, a DCGI-approved cell therapy for Grade II–III Knee Osteoarthritis, offering long-term ...

An Osaka Metropolitan University-led research team found that patients with knee osteoarthritis show a weaker human-body ...

Please provide your email address to receive an email when new articles are posted on . Knee osteoarthritis accounts for about 80% of the burden of OA worldwide, and published studies show it ...

Approved by the Drug Controller General of India (DCGI), the treatment offers to slow disease progression and promote ...

Patients with osteoarthritis (OA) primarily affecting only one knee joint compartment did just as well with partial knee replacement (PKR) as with total arthroplasty after 10 years in a randomized ...

New research shows that corticosteroid injections for knee OA treatment do not hasten a patient's progression to a total knee replacement when compared with hyaluronic acid injections. Details of this ...

Please provide your email address to receive an email when new articles are posted on . Use of corticosteroid injections did not exacerbate radiographic progression of knee osteoarthritis or ...

The purpose of the current study was to characterize the gait profile of patients with knee OA compared to matched controls using a new measuring system that can be applied in clinic settings rather ...

Biomechanical footwear calibrated for individual use demonstrated a significant improvement in the pain scores of individuals with knee osteoarthritis after 24 weeks in a recent trial. Although the ...

Phase 1b safety data at 6 month post-administration and Day 84 efficacy data available for all patients enrolled. No dose limiting toxicities at any of the doses tested (up to 30 ug) at 6 months ...